Data on prior pegylated liposomal doxorubicin (PLD) treatment in recurrent ovarian cancer: Posthoc data analysis from the phase 3 randomize d, open-lab el study comparing trab ecte din and PLD versus PLD alone in patients with recurrent ovarian cancer

被引：1

作者：

Monk, Bradley J. ^{[1
]}

Herzog, Thomas J. ^{[2
]}

Wang, George ^{[3
]}

Triantos, Spyros ^{[3
]}

Maul, Scott ^{[4
]}

Knoblauch, Roland ^{[3
]}

McGowan, Tracy ^{[5
]}

Shalaby, Waleed S. W. ^{[5
]}

Coleman, Robert L. ^{[6
]}

机构：

[1] Creighton Univ, Univ Arizona, US Oncol Network, Arizona Oncol, Phoenix, AZ 85012 USA

[2] Univ Cincinnati, Canc Ctr, Cincinnati, OH USA

[3] Janssen Res & Dev, Spring House, PA USA

[4] Janssen Res & Dev, Los Angeles, CA USA

[5] Janssen Sci Affairs LLC, Horsham, PA USA

[6] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

DATA IN BRIEF | 2020年 / 30卷

关键词：

Overall survival; Pegylated liposomal doxorubicin; Trabectedin; Recurrent ovarian cancer; Response rate;

D O I：

10.1016/j.dib.2020.105465

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

The data presented herein are supplementary to our published primary article "A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer"[1]. The exploratory analysis evaluated the impact of prior pegylated liposomal doxorubicin (PLD) therapy in patients who participated in a randomized, open-label study comparing combination therapy of trabectedin and PLD vs PLD alone in third-line recurrent ovarian cancer (ROC). These exploratory analyses showed that prior treatment with PLD in ROC does not impact the response and survival rates nor does it increase toxicities or negatively influence survival and response rates in both treatment groups. (C) 2020 The Author(s). Published by Elsevier Inc.

引用

页数：7

共 50 条

[31] RESULTS OF A RANDOMIZED, OPEN-LABEL, PHASE III TRIAL OF PATUPILONE (P) VERSUS PEGYLATED LIPOSOMAL DOXORUBICIN (PLD) IN TAXANE/PLATINUM REFRACTORY/RESISTANT PATIENTS WITH RECURRENT OVARIAN, FALLOPIAN, OR PERITONEAL CANCER
Colombo, N.
Schwartz, P. E.
Bamias, A.
Bae, D. S.
Rzepka-Gorska, I.
Kaye, S. B.
Conte, P. F.
Weber, D.
Li, J.
Kutarska, E.
ANNALS OF ONCOLOGY, 2010, 21 : 11 - 11
[32] Trabectedin plus pegylated liposomal doxorubicin (PLD) in patients with platinum-sensitive recurrent ovarian cancer (PSROC) regardless of prior use of antiangiogenics: First results of an observational, prospective study
Pignata, S.
Scambia, G.
Mazzei, T.
Arruti Barbia, M.
Naglieri, E.
de Sande, L. M.
ANNALS OF ONCOLOGY, 2018, 29 : 352 - 352
[33] Addition of vandetanib to pegylated liposomal doxorubicin (PLD) in patients with recurrent ovarian cancer. A randomized phase I/II study of the AGO Study Group (AGO-OVAR 2.13)
Philipp Harter
Jalid Sehouli
Rainer Kimmig
Jörn Rau
Felix Hilpert
Christian Kurzeder
Gabriele Elser
Andreas du Bois
Investigational New Drugs, 2013, 31 : 1499 - 1504
[34] Addition of vandetanib to pegylated liposomal doxorubicin (PLD) in patients with recurrent ovarian cancer. A randomized phase I/II study of the AGO Study Group (AGO-OVAR 2.13)
Harter, Philipp
Sehouli, Jalid
Kimmig, Rainer
Rau, Joern
Hilpert, Felix
Kurzeder, Christian
Elser, Gabriele
du Bois, Andreas
INVESTIGATIONAL NEW DRUGS, 2013, 31 (06) : 1499 - 1504
[35] Extending platinum-free interval (PFI) in partially platinum-sensitive (PPS) patients (pts) with recurrent ovarian cancer (ROC) treated with trabectedin (Tr) plus pegylated liposomal doxorubicin (Tr plus PLD) versus PLD alone: Results from a PPS cohort of a phase III study
Poveda, A.
Tjulandin, S.
Kong, B.
Roy, M.
Chan, S.
Filipczyk-Cisarz, E.
Hagberg, H.
Lebedinsky, C.
Parekh, T. V.
Monk, B. J.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[36] A GINECO phase I study evaluating lenalidomide (Le) combined with pegylated liposomal doxorubicin (PLD) and carboplatin (C) in late (>6 months) recurrent ovarian cancer (LROC) patients (pts).
Selle, Frederic
Lesoin, Anne
Kaminsky, Marie-Christine
Follana, Philippe
Ray-Coquard, Isabelle
Berton-Rigaud, Dominique
Floquet, Anne
Hardy-Bessard, Anne-Claire
Joly, Florence
Pujade-Lauraine, Eric
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[37] TRABECTEDIN PLUS PEGYLATED LIPOSOMAL DOXORUBICIN (PLD) PRIOR TO SUBSEQUENT PLATINUM-BASED CHEMOTHERAPY IN RECURRENT OVARIAN CANCER (ROC): RESULTS FROM OVA-301 FOLLOW-UP
Colombo, N.
Tanovic, A.
Fernandez, C.
Casado Herraez, A.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2014, 24 (09) : 452 - 453
[38] Model prediction of mean PFS and OS Time from a phase II trial comparing vintafolide (V) plus pegylated liposomal doxorubicin (PLD), versus PLD alone, in platinum-resistant ovarian cancer (PROC) patients with 100% folate receptor (FR) positive target lesions
Herzog, T.
Anderson, K.
Wang, J.
Xu, R.
EUROPEAN JOURNAL OF CANCER, 2013, 49 : S732 - S733
[39] Phase III randomized trial of maintenance pegylated liposomal doxorubicin (PLD) / carboplatin versus without in patients with advanced ovarian cancer: An Asian Gynecologic Oncology Group study.
Lai, Chyong-Huey
Vallikad, Elizabeth
Lin, Hao
Yang, Lan-Yan
Ou, Yu-Che
Chou, Hung-Hsueh
Lin, Cheng-Tao
Huang, Huei-Jean
Huang, Kung-Gen
Qiu, Jentai
Hung, Yao-Ching
Wu, Tzu-I
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[40] Extending platinum-free interval (PFI) in partially platinum-sensitive (PPS) patients (pts) with recurrent ovarian cancer (ROC) treated with trabectedin (Yondelis®) plus pegylated liposomal doxorubicin (Caelyx®[PLD]) combination versus PLD alone: Results from a PPS cohort of the OVA-301 phase III study
Lehmann-Willenbrock, E.
Runnebaum, I
Nieto, A.
Poveda, A.
Monk, B. J.
De la Riba, M., I
Meerpohl, H-G
ONKOLOGIE, 2010, 33 : 190 - 190

← 1 2 3 4 5 →